Q4 2025 Embla Medical hf Earnings Call Transcript
Key Points
- Embla Medical hf (OSSUY) achieved solid organic sales growth of 6% for the full year 2025, driven by strong performance in prosthetics and neuro orthotics.
- The company completed a majority investment in Streifenitter, enhancing its position as a full-range provider in the prosthetics market.
- Embla Medical hf (OSSUY) introduced new innovative products, including two bionic knees, Navi and Ion, and the Odyssey IQA bionic foot.
- The company opened its first clinic in Ukraine, demonstrating a commitment to providing high-quality mobility care in challenging environments.
- Embla Medical hf (OSSUY) was recognized among the world's TOP500 companies for sustainable growth, marking the second consecutive year of this achievement.
- The EBITA margin for the fourth quarter decreased to 19% from 21% in the same quarter of the previous year.
- Sales in the Americas were flat, with 0% organic growth, partly due to a competitive environment and price erosion in the bracing business.
- The company faced challenges in its patient care business, with lower than expected growth due to internal change initiatives causing temporary disruptions.
- Tariffs and FX impacts negatively affected the company's financial performance, with tariffs impacting the EBITA margin by approximately 3% points in the quarter.
- The restructuring initiatives in patient care have been costly, impacting both COGS and OpEx by approximately $2 million in the quarter.
At this time, I would like to welcome everyone to this Embla Medical Q4 and Annual Report for 2025 Conference Call. Today's call is being recorded.
If you have any objections, please disconnect at this time. (Operator Instructions) I'll now turn the call over to your speakers. You may now begin.
¶-
Thank you very much, operator.
Good morning and welcome to the Emle Medical conference call where we will review the fourth quarter and full year results for 2025. I'm Solvason, President and CEO of Emple Medical.
Today, also joining me here is our Chief Financial Officer, Armasensdotter and ELA Medical's Head of Industrial relations, Klaus Sintas.
The presentation should take approximately 20 minutes, after which there will be an opportunity to ask questions during a Q&A session.
If you can please go to the next slide.
2025 was a year of meaningful progress for Emblemedical with several milestones as we continue to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
